The experience of the parenteral form of ibandrinic acid administration in different clinical situations of treatment of postmenopausal osteoporosis
https://doi.org/10.26295/OS.2020.35.27.007
Abstract
The article presents two clinical cases illustrating the experience of using ibandronate in patients with different clinical types of postmenopausal osteoporosis, including those undergoing medical rehabilitation procedures. Ibandronic acid is highly effective in reducing of vertebral fracture risk and in increasing spinal bone mineral density and also has a good tolerance, safety profile and a convenient administration regimen. Given the evidence base of clinical trials, ibandronate may be a treatment option for postmenopausal women with uncomplicated osteoporosis and with osteoporotic fractures. In particular, the appointment of the drug is justified in patients undergoing rehabilitation after an osteoporotic fracture and associated surgical treatment. Physical therapy in combination with the prescription of pharmaceuticals affecting the bone remodeling allows achieving better results in the rehabilitation of patients with osteoporotic fractures.
About the Authors
L. A. Marchenkova
FSBI «National Medical Research Center of Rehabilitation and Balneology» of Ministry of Health of Russian Federation
Russian Federation
Russian Federation
Moscow
E. V. Makarova
FSBI «National Medical Research Center of Rehabilitation and Balneology» of Ministry of Health of Russian Federation
Russian Federation
Russian Federation
Moscow
References
1. Camacho P. M., Petak S. M., Binkley N., Diab D. L., Eldeiry L. S., Farooki A., Harris S. T., Hurley D. L., Kelly J., Lewiecki E. M., Pessah-Pollack R., McClung M., Wimalawansa S. J., Watts N. B. American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2020 Update. EXECUTIVE SUMMARY // Endocr Pract. 2020; 26 (5): 564-570. DOI: 10.4158/GL-2020-0524.
2. Kanis J. A., Harvey N. C., McCloskey E., Bruyère O., Veronese N., Lorentzon M., Cooper C., Rizzoli R., Adib G., Al-Daghri N., Campusano C., Chandran M., Dawson-Hughes B., Javaid K., Jiwa F., Johansson H., Lee J. K., Liu E., Messina D., Mkinsi O., Pinto D., Prieto-Alhambra D., Saag K., Xia W., Zakraoui L., Reginster J. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures // Osteoporos Int. 2020; 31 (1): 1-12. DOI: 10.1007/s00198-019-05176-3. Epub 2019 Nov 13. Erratum in: Osteoporos Int. 2020; 31 (4): 797-798.
3. Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis and the prevention of fragility fractures. Revised edition. Edinburgh: SIGN. 2020. 144 p. Режим доступа: https://www.sign.ac.uk/media/1741/sign142.pdf.
4. Bartl R., Goette S., Hadji P., Hammerschmidt T. Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis ECCEO, 2005 Poster (P195).
5. Marchenkova L. A., Makarova E. V., Gerasimenko M. Yu. Rasprostranennost osteoporoza, assotsiiruyuschikhsya s nim perelomov i urovnya informirovannosti po probleme sredi patsientov, prokhodyaschikh meditsinskuyu reabilitatsiyu [Prevalence of osteoporosis, associated fractures, and level of knowledge about this problem among the patients undergoing medical rehabilitation] // Lechaschii vrach. 2020, № 2, р. 54-57. (In russ.)
6. Marchenkova L. A., Makarova E. V., Gerasimenko M. Yu. Otsenka riska osteoporoticheskikh perelomov i rasprostranennosti osteoporoza u patsientov v vozraste 50 let i starshe, prokhodyaschikh meditsinskuyu reabilitatsiyu [Assesment of osteoporotic fractures risk and osteoporosis prevalence among patients over 50 years old undergoing medical rehabilitation] // Fizioterapiya, balneologiya i reabilitatsiya. 2020; 19 (1), р. 13-19. (In russ.)
7. Baus F., Lalla S., Endele R., Hothorn L. H. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats // J. Rheumatology. 2002, vol. 29, pp. 2200-2208.
8. Chesnut III C. H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis // J Bone Miner Res. 2004; 19: 1241-1249.
9. Bauss F., Schimmer R. C. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis // Ther Clin Risk Manag. 2006; 2 (1): 3-18.
10. Inderjeeth C. A., Glendenning P., Ratnagobal S., Inderjeeth D. C., Ondhia C. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis // Int J Womens Health. 2014; 7: 7-17. Published 2014 Dec 17. DOI: 10.2147/IJWH.S73944.
11. Recker R. R., Ste-Marie L. G., Langdahl B., et al. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study // Bone. 2010. Vol. 46. P. 660-665.
12. Cranney A., Wells G., Adachi R. Non-vertebral fracture reduction with highversus low-dose ibandronate: meta-analysis of individual patient data // Ann Rheum Dis. 2007; 66 (suppl. 2): 681.
13. Miller P. D., Recker R. R., Reginster J. Y., Riis B. J., Czerwinski E., Masanauskaite D., Kenwright A., Lorenc R., Stakkestad J. A., Lakatos P. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study // Osteoporos Int. 2012; 23 (6): 1747-1756. DOI: 10.1007/s00198-011-1773-0.
14. Reginster J.-Y., Adami S., Lakatos P., Greenwald M., Stepan J. J., Silverman S. L., Christiansen C., Rowell L., Mairon N., Bonvoisin B., Drezner M. K., Emkey R., Felsenberg D., Cooper C., Delmas P. D., Miller P. D. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study // Ann Rheum Dis. 2006; 65 (5): 654-661. DOI: 10.1136/ard.2005.044958.
15. Bianchi G., Czerwinski E., Kenwright A., Burdeska A., Recker R. R., Felsenberg D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension // Osteoporos Int. 2012; 23 (6): 1769-1778. DOI: 10.1007/s00198-011-1793-9.
16. Bala Y., Kohles J., Recker R. R., et al. Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization // Calcified Tissue Int. 2013. Vol. 92. P. 6-14.
17. Recker R. R., Ste-Marie L. G., Langdahl B., et.al. Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral ibandronate Osteoporosis vertebral fracture trial in North America and Europe study // J. Clin Densitom. 2009. Vol. 12. P. 71-76.
18. Tosteoson A. N., Grove M. R., Hammond C. S., Moncur M. M., Ray G. T., Hebert G. M., Pressman A. R., Ettinger B. Early discontinuation of treatment for osteoporosis // American J. Medicine. 2003, vol. 115, pp. 209-216.
19. Hamilton B., McCoy K., Taggert H. Tolerability and compliance with residronate in clinical practice // Osteoporosis International. 2003, vol. 14, pp. 259-262.
20. Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas V., Masanauskaite D. Patient preference for once-monthly ibandronate versus onceweekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) // Curr Med Res Opin. 2005; 21 (12): 1895-1903. DOI: 10.1185/030079905X74862.
21. Cooper A., Drake J., Brankin E. PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study // Int J Clin Pract. 2006; 60 (8): 896-905. DOI: 10.1111/j.1742-1241.2006.01059.x.
22. Peter C. P., Handt L. K., Smith S. M. Esophageal irritation due to alendronate sodium tablets: possible mechanisms // Digestive Disease Sciences. 1998, vol. 43, pp. 1998-2002.
23. Inderjeeth C. A., Glendenning P., Ratnagobal S., Inderjeeth D. C., Ondhia C. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal.
Review
For citations:
Marchenkova L.A., Makarova E.V. The experience of the parenteral form of ibandrinic acid administration in different clinical situations of treatment of postmenopausal osteoporosis. Lechaschi Vrach. 2020;(10):31-35. (In Russ.) https://doi.org/10.26295/OS.2020.35.27.007
Views:
310
JATS XML
Email this article 
